Squalene-containing nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of diphencyprone for treating alopecia areata

Pharmaceutical Research

Volumn 30, Issue 2, 2013, Pages 435-446

  Lin, Yin Ku ^a,b   Al Suwayeh, Saleh A ^c   Leu, Yann Lii ^a   Shen, Feng Ming ^a   Fang, Jia You ^a,d  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

alopecia areata; diphencyprone; hair follicles; nanostructured lipid carriers; percutaneous absorption

Indexed keywords

CYANOACRYLATE; DIPHENCYPRONE; NANOCARRIER; PHOSPHATIDYLCHOLINE; SQUALENE; SURFACTANT;

ALOPECIA AREATA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; HAIR FOLLICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LIPOPHILICITY; MOLECULAR MODEL; MOUSE; NANOANALYSIS; NANOCHEMISTRY; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SKIN ABSORPTION; SKIN BIOPSY; STRATUM CORNEUM; ZETA POTENTIAL;

ALOPECIA AREATA; ANIMALS; CYCLOPROPANES; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FEMALE; HAIR FOLLICLE; KERATINOCYTES; MICE; MICE, NUDE; NANOSTRUCTURES; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; SKIN; SKIN ABSORPTION; SQUALENE; SURFACE-ACTIVE AGENTS;

EID: 84873449012     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0888-0     Document Type: Article

References (42)

1. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG. Guidelines for the management of alopecia areata. Br J Dermatol. 2003;149:692-9.
2. Pazoki-Toroudi H, Ajami M, Babakoohi S, Khaki L, Habibey R, Akhiani M, et al. Effects of diphencyprone on expression of Bcl-2 protein in patients with alopecia areata. Immunopharmacol Immunotoxicol. 2010;32:422-5.
3. El-Zawahry BM, Bassiouny DA, Khella A, Zaki NS. Five-year experience in the treatment of alopecia areata with DPC. J Eur Acad Dermatol Venereol. 2010;24:264-9.
4. Avgerinou G, Gregoriou S, Rigopoulos D, Stratigos A, Kalogeromitros D, Katsambas A. Alopecia areata: topical immunotherapy treatment with diphencyprone. J Eur Acad Dermatol Venereol. 2008;22:320-3.
5. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update. Part II. Treatment. J Am Acad Dermatol. 2010;62:191-202.
6. Pires MC, Martins JM, Montealegre F, Gatti FR. Vitiligo after diphencyprone for alopecia areata. Dermatol Res Pract. 2010;2010:171265.
7. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131-55.
8. González-Mira E, Nikolić S, García ML, Egea MA, Souto EB, Calpena AC. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen. J Pharm Sci. 2011;100:242-51.
9. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137:1063-8.
10. Puglia C, Bonina F, Rizza L, Blasi P, Schoubben A, Perrotta R, et al. Lipid nanoparticles as carrier for octyl-methoxycinnamate: in vitro percutaneous absorption and photostability studies. J Pharm Sci. 2012;101:301-11.
11. Baroli B, Ennas MG, Loffredo F, Isola M, Pinna R, López-Quintela MA. Penetration of metallic nanoparticles in human full-thickness skin. J Invest Dermatol. 2007;127:1701-12.
12. Zhang LW, Monteiro-Riviere NA. Assessment of quantum dot penetration into intact, tape-stripped, abraded and flexed rat skin. Skin Pharmacol Physiol. 2008;21:166-80.
13. Teichmann A, Jacobi U, Ossadnik M, Richter H, Koch S, Sterry W, et al. Differential stripping: determination of the amount of topically applied substances penetrated into the hair follicles. J Invest Dermatol. 2005;125:264-9.
14. Betz G, Imboden R, Imanidis G. Interaction of liposome formulations with human skin in vitro. Int J Pharm. 2001;229:117-29.
15. Wen CJ, Zhang LW, Al-Suwayeh SA, Yen TC, Fang JY. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomed. 2012;7:1599-611.
16. Hsu SH, Wen CJ, Al-Suwayeh SA, Chang HW, Yen TC, Fang JY. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers (NLCs) for targeting the brain: apomorphine as a model drug. Nanotechnology. 2010;21:405101.
17. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. Podophyllotoxin- loaded solid lipid nanoparticles for epidermal targeting. J Contr Rel. 2006;110:296-306.
18. Zimmermann E, Müller RH. Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN®) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm. 2001;52:203-10.
19. Müller RH, Runge SA, Ravelli V, Thünemann AF, Mehnert W, Souto EB. Cyclosporine-loaded solid lipid nanoparticles (SLN®): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm. 2008;68:535-44.
20. Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur J Pharm Sci. 2009;38:138-46.
21. Schubert MA, Harms M, Müller-Goymann CC. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur J Pharm Sci. 2006;27:226-36.
22. Happle R. Diphencyprone for the treatment of alopecia areata: more data and new aspects. Arch Dermatol. 2002;138:112-3.
23. Gopee NV, Roberts DW, Webb P, Cozart CR, Siitonen PH, Latendresse JR, et al. Quantitative determination of skin penetration of PEG-coated CdSe quantum dots in dermabraded but not intact SKH-1 hairless mouse skin. Toxicol Sci. 2009;111:37-48.
24. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci. 2010;99:21-50.
25. Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, et al. Lipid nanoparticles for skin penetration enhancement- correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Contr Rel. 2005;110:151-63.
26. Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007;59:427-43.
27. Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol. 2010;27:247-59.
28. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366:170-84.
29. Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers, and solid lipid nanoparticles. J Microencapsul. 2009;26:734-47.
30. Abdel-Mottaleb MMA, Neumann D, Lamprecht A. Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers. Eur J Pharm Biopharm. 2011;79:36-42.
31. Liu KS, Wen CJ, Yen TC, Sung KC, Ku MC, Wang JJ, et al. Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers (NLCs) for efficient brain targeting. Nanotechnology. 2012;23:095103.
32. Knorr F, Lademann J, Patzelt A, Sterry W, Blume-Peytavi U, Vogt A. Follicular transport route-research progress and future perspectives. Eur J Pharm Biopharm. 2009;71:173-80.
33. Jung S, Patzelt A, Otberg N, Thiede G, Sterry W, Lademann J. Strategy of topical vaccination with nanoparticles. J Biomed Opt. 2009;14:021001.
34. Messenger AG. Alopecia areata. Eur J Dermatol. 2006;16:537-42.
35. Küchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, et al. Nanoparticles for skin penetration enhancement-a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm. 2009;71:243-50.
36. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009;66:2873-96.
37. Lu W, Sun Q, Wan J, She Z, Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res. 2006;66:11878-87.
38. Lv Q, Yu A, Xi Y, Li H, Song Z, Cui J, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009;372:191-8.
39. Alvarez-Román R, Naik YN, Fessi H, Guy RH. Visualization of skin penetration using confocal laser scanning microscopy. Eur J Pharm Biopharm. 2004;58:301-16.
40. Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J. Variations of hair follicle size and distribution in different body sites. J Invest Dermatol. 2004;122:14-9.
41. Frum Y, Bonner MC, Eccleston GM, Meidan VM. The influence of drug partition coefficient on follicular penetration: in vitro human skin studies. Eur J Pharm Sci. 2007;30:280-7.
42. Trauer S, Patzelt A, Otberg N, Knorr F, Rozycki C, Balizs G, et al. Permeation of topically applied caffeine through human skin-a comparison of in vivo and in vitro data. Br J Clin Pharmacol. 2009;68:181-6.